Claims
- 1. A cryptophycin represented by the structure: ##STR47## wherein: Ar is phenyl or any unsubstituted or substituted aromatic or heteroaromatic group;
- R.sub.1 is a halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkythio, dialkysulfonium, sulfate, or phosphate;
- R.sub.2 is OH or SH; or
- R.sub.1 and R.sub.2 may be taken together to form an epoxide ring, an aziridene ring, an episulfide ring, a sulfate ring or a monoalkylphosphate ring; or
- R.sub.1 and R.sub.2 may be taken together to form a second bond between C.sub.18 and C.sub.19 ;
- R.sub.3 is a lower alkyl group;
- R.sub.4 is H;
- R.sub.5 is H;
- R.sub.4 and R.sub.5 may be taken together to form a second bond between C.sub.13 and C.sub.14 ;
- R.sub.6 is a benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihalohydroxybenzyl group;
- R.sub.7 is H or a lower alkyl group;
- R.sub.8 is H or a lower alkyl group;
- R.sub.9 is H or a lower alkyl group;
- R.sub.10 is H or a lower alkyl group;
- X is O, NH or alkylamino; and
- Y is O, NH or alkylamino
- wherein the following structures are excluded: ##STR48##
- 2. The cryptophycin of claim 1, wherein R.sub.8 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl.
- 3. The cryptophycin of claim 1, wherein R.sub.7 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl.
- 4. The cryptophycin of claim 1, wherein R.sub.7 is H, R.sub.8 is methyl, R.sub.3 is methyl; X and Y are not both O.
- 5. The cryptophycin of claim 1, wherein R.sub.3 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl.
- 6. The cryptophycin of claim 1, wherein R.sub.9 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl.
- 7. The cryptophycin of claim 1, wherein R.sub.10 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl.
- 8. The compound of claim 1, wherein at least one of the groups attached to C.sub.3, C.sub.6, C.sub.10, C.sub.16, C.sub.17 and C.sub.18 have R stereochemistry.
- 9. The compound of claim 1, wherein at least one of the groups attached to C.sub.3, C.sub.6, C.sub.10, C.sub.16, C.sub.17 and C.sub.18 have S stereochemistry.
- 10. The compound of claim 1, wherein R.sub.1 and R.sub.2 are taken together to form a second bond between C.sub.18 and C.sub.19, R.sub.3, R.sub.7 and R.sub.8 are methyl, R.sub.4 and R.sub.5 are taken together to form a second bond between C.sub.13 and C.sub.14 such that there is a double bond, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 11. The compound of claim 1, wherein R.sub.1 and R.sub.2 are taken together to form a R,R-epoxide ring, R.sub.3, R.sub.7 and R .sub.8 are methyl, R.sub.4 and R.sub.5 are taken together to form a second bond between C.sub.13 and C.sub.14 such that there is a double bond, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 12. The compound of claim 1, wherein R.sub.1 and R.sub.2 are taken together to form a S,S-epoxide ring, R.sub.3, R.sub.7 and R .sub.8 are methyl, R.sub.4 and R.sub.5 are taken together to form a second bond between C.sub.13 and C.sub.14 such that there is a double bond, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 13. The compound of claim 1, wherein R.sub.1 is chloro, R.sub.2 is hydroxyl, R.sub.3, R.sub.7 and R.sub.8 are methyl, R.sub.4 and R.sub.5 are taken together to form a second bond between C.sub.13 and C.sub.14 such that there is a double bond, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 14. The compound of claim 1, wherein R.sub.1 and R.sub.2 are taken together to form an epoxide ring, R.sub.3, R.sub.7 and R .sub.8 are methyl, R.sub.4 and R.sub.5 are hydrogen, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 15. The compound of claim 1, wherein R.sub.1 is chloro, R.sub.2 is hydroxyl, R.sub.3, R.sub.7 and R .sub.8 are methyl, R.sub.4 and R.sub.5 are hydrogen, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 16. The compound of claim 1, wherein R.sub.1 and R.sub.2 are taken together to form a R,R-episulfide ring, R.sub.3, R.sub.7 and R .sub.8 are methyl, R.sub.4 and R.sub.5 are taken together to form a second bond between C.sub.13 and C.sub.14 such that there is a double bond, R.sub.6 is 3-chloro-4-methoxybenzyl, R.sub.9 is isobutyl, R.sub.10 is hydrogen, and X and Y are oxygen.
- 17. A pharmaceutical composition for inhibiting proliferation of a hyperproliferative mammalian cell comprising an effective amount of a compound with the following structure: ##STR49## wherein: Ar is phenyl or any unsubstituted or substituted aromatic or heteroaromatic group;
- R.sub.1 is a halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkythio, dialkysulfonium, sulfate, or phosphate;
- R.sub.2 is OH or SH; or
- R.sub.1 and R.sub.2 may be taken together to form an epoxide ring, an aziridene ring, an episulfide ring, a sulfate ring or a monoalkylphosphate ring; or
- R.sub.1 and R.sub.2 may be taken together to form a second bond between C.sub.18 and C.sub.19 ;
- R.sub.3 is a lower alkyl group;
- R.sub.4 is H;
- R.sub.5 is H;
- R.sub.4 and R.sub.5 may be taken together to form a second bond between C.sub.13 and C.sub.14 ;
- R.sub.6 is a benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihalohydroxybenzyl group;
- R.sub.7 is H or a lower alkyl group;
- R.sub.8 is H or a lower alkyl group;
- R.sub.9 is H or a lower alkyl group;
- R.sub.10 is H or a lower alkyl group;
- X is O, NH or alkylamino; and
- Y is O, NH or alkylamino
- wherein the following structures are excluded: ##STR50## together with a pharmaceutically acceptable carrier.
- 18. The pharmaceutical composition of claim 17 further comprising at least one anti-mitotic antitumor agent in addition to said compound.
- 19. A method for inhibiting proliferation of a mammalian cell comprising contacting the mammalian cell with a cryptophycin compound in an amount sufficient to inhibit the proliferation of the cell, the cryptophycin compound having the following structure: ##STR51## wherein: Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group; R.sub.1 is a halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkythio, dialkysulfonium, sulfate, or phosphate;
- R.sub.2 is OH or SH; or
- R.sub.1 and R.sub.2 may be taken together to form an epoxide ring, an aziridene ring, an episulfide ring, a sulfate ring or a monoalkylphosphate ring; or
- R.sub.1 and R.sub.2 may be taken together to form a second bond between C.sub.18 and C.sub.19 ;
- R.sub.3 is a lower alkyl group;
- R.sub.4 is H;
- R.sub.5 is H;
- R.sub.4 and R.sub.5 may be taken together to form a second bond between C.sub.13 and C.sub.14 ;
- R.sub.6 is a benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihalohydroxybenzyl group;
- R.sub.7 is H or a lower alkyl group;
- R.sub.8 is H or a lower alkyl group;
- R.sub.9 is H or a lower alkyl group;
- R.sub.10 is H or a lower alkyl group;
- X is O, NH or alkylamino; and
- Y is O, NH or alkylamino.
- 20. The method of claim 19 further comprising contacting the cell with at least one anti-mitotic antitumor agent in addition to said compound.
- 21. The method of claim 20, wherein said anti-mitotic antitumor agent is selected from agents which inhibit formation of microtubules by sequestering tubulin, agents with induce formation of paracrystalline aggregates of tubulin or agents which promote the polymerization of tubulin.
- 22. The method of claim 20, wherein said anti-mitotic antitumor agent is selected from colchicine, colcemid, vinblastine, vincristine or taxol.
- 23. The method of claim 19, wherein the mammalian cell is hyperproliferative.
- 24. The method of claim 23, wherein the hyperproliferative cell is human.
- 25. A method for inhibiting proliferation of a hyperproliferative mammalian having a multiple drug resistant phenotype comprising contacting the cell with an amount of a cryptophycin compound effective to disrupt the dynamic state of microtubule polymerization and depolymerization to arrest cell mitosis, thereby inhibiting the proliferation of the cell, the cryptophycin compound having the following structure: ##STR52## wherein: Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group;
- R.sub.1 is a halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkythio, dialkysulfonium, sulfate, or phosphate;
- R.sub.2 is OH or SH; or
- R.sub.1 and R.sub.2 may be taken together to form an epoxide ring, an aziridene ring, an episulfide ring, a sulfate ring or a monoalkylphosphate ring; or
- R.sub.1 and R.sub.2 may be taken together to form a second bond between C.sub.18 and C.sub.19 ;
- R.sub.3 is a lower alkyl group;
- R.sub.4 is H;
- R.sub.5 is H;
- R.sub.4 and R.sub.5 may be taken together to form a second bond between C.sub.13 and C.sub.14 ;
- R.sub.6 is a benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihalohydroxybenzyl group;
- R.sub.7 is H or a lower alkyl group;
- R.sub.8 is H or a lower alkyl group;
- R.sub.9 is H or a lower alkyl group;
- R.sub.10 is H or a lower alkyl group;
- X is O, NH or alkylamino; and
- Y is O, NH or alkylamino.
RELATED APPLICATIONS
This is a continuation-in-part of International Application No. PCT/US94/14740, filed Dec. 21, 1994, which is a continuation-in-part of U.S. Application No. 08/249,955, filed May 27, 1994, now abandoned, which is a continuation of U.S. Application No. 08/172,632, filed Dec. 21, 1993, now abandoned. These patent applications are hereby incorporated by reference.
Government Interests
This invention was made in part with U.S. Government support under Grant Nos. CA/12623 and CA53001 from The National Cancer Institute, Department of Health and Human Services. Accordingly, the U.S. Government may have certain rights in this invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4845086 |
Sesin |
Jul 1989 |
|
Non-Patent Literature Citations (4)
Entry |
Smith et al., Cancer Research vol. 54 (Jul. 1994) 3779-84. |
Ttimurtulu et al., JACS vol. 116, 4729-37 (1994). |
Kubayoshi et al, Chem. Pharm. Bull. vol. 42(16) (Oct. 1994) pp. 2196-98. |
Goodman & Gilman, "The Pharmacological Basis of Therapeutics" 6th Ed. (MacMillan Publishing 1980) pp. 1249-1255; 1738-1740. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
172632 |
Dec 1993 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
PCTUS9414740 |
Dec 1994 |
|
Parent |
249955 |
May 1994 |
|